Body composition — Oct 2021 to Mar 2026

1,090 measurements · smart scale data · Aurora Villarroel DOB 05/22/1970
Total weight lost
-52.8 lb
peak 205.9 → 153.1 lbs
Fat mass lost
-40.5 lb
since Jan 2025
Muscle mass lost
-6.9 lb
Jan 2025 → Mar 2026
Visceral fat
16 → 8
peak to current (halved)
Body fat %
45.8 → 32.0%
peak to current
BMR change
-233 kcal
1594 → 1361 kcal/day
Metabolic age
63 → 59
peak to current
Current BMI
26.1
down from 35.1 at peak
Weight
Fat vs muscle
Visceral fat
BMR & metabolic age
Integrated analysis
Show:
Weight (lbs) Key events
Body fat % Muscle mass (lbs, right axis)
Fat vs lean mass composition of weight loss (Jan 2025 → Mar 2026)
Total weight lost
47.5 lbs
Fat mass lost
40.5 lbs (85.3% of loss)
Lean/muscle mass lost
6.9 lbs (14.7% of loss)
Assessment
85% fat loss is a favorable composition ratio for GLP-1/GIP agonist therapy. Published tirzepatide trials (SURMOUNT-1) showed ~70% fat / ~30% lean mass ratio. This ratio is better than the clinical trial average, suggesting good protein intake (daily salmon) and preserved muscle mass despite significant total loss.
Visceral fat score (scale 1–25)
Visceral fat significance
Oct 2024 peak
16 — elevated (healthy range: 1–12)
Mar 2026 current
8 — normal range
Reduction
50% decrease in visceral fat score
Clinical relevance
Visceral fat drives insulin resistance, systemic inflammation (CRP), and autoimmune dysregulation. Reducing from 16 to 8 directly correlates with HbA1c normalizing (5.9%→5.3%), CRP falling (3.12→0.4 mg/L), and improved autoimmune load tolerance.
BMR (kcal/day) Metabolic age (right axis)
BMR decline — adaptive thermogenesis vs expected
BMR at peak (Oct 2024)
1,594 kcal/day
BMR current (Mar 2026)
1,361 kcal/day (-233 kcal)
Expected from weight loss
~150–180 kcal reduction from mass alone. Actual drop of 233 kcal suggests ~50–80 kcal of adaptive thermogenesis — typical for significant weight loss.
Metabolic age
Dropped from 63 to 59 — still 5 years above chronological age (54). Target: rebuild lean mass to bring metabolic age down toward chronological age.
Phase 1 — Oct 2021 – Oct 2023: weight cycling
Range
171–198 lbs with significant cycling. Muscle mass was higher in this period (up to 122 lbs in Aug 2022). The rebound from 171 to 196 lbs (Jan–Mar 2023, +25 lbs) likely marks onset of thyroid deterioration.
Visceral fat
Ranged 9–12, generally well-controlled in 2021–2022, worsening through 2023.
Phase 2 — Oct 2023 – Nov 2024: scale malfunction gap + peak weight
Data gap note
Old scale malfunctioned Oct 2023 – May 2024, showing false losses. Real weight was increasing during this period. New scale data from May 2024 confirms true trajectory.
Oct 2024 peak
205.9 lbs, 45.8% body fat, visceral fat 16, metabolic age 63. Coincides exactly with TSH 8.77 on Oct 31, 2024 — uncontrolled hypothyroidism driving fat accumulation.
Phase 3 — Feb 2025 – Mar 2026: Zepbound intervention
Start weight
~200 lbs (Feb 2025) → 153 lbs (Mar 2026) = -47 lbs in 13 months
Rate of loss
Fastest Mar–Jun 2025 (~5 lbs/month at ~5 mg dose). Plateau at 151–154 lbs since Nov 2025 on 7.5 mg — 4+ months stable.
Composition ratio
85% fat / 15% lean — better than SURMOUNT-1 trial average (~70/30). Daily salmon protein intake likely protective of lean mass.
Muscle mass concern
Absolute muscle mass at 97.8 lbs is low for age 54F at 153 lbs. Sarcopenia risk warrants resistance training and creatine consideration (3–5 g/day) — discuss with prescriber.
Supplement implications from body composition data
Protein target
With BMR at 1,361 kcal and muscle mass declining, target 110–130g protein/day minimum. Daily salmon supports this.
Creatine monohydrate
3–5 g/day — evidence-based intervention for preserving lean mass during caloric restriction. Also reduces SAM-e demand, benefiting COMT methylation. Discuss with prescriber.
Visceral fat and CRP link
Visceral fat 16→8 directly explains CRP dropping 3.12→0.4 mg/L. Visceral adipose tissue is a major source of IL-6 and TNF-α. Continued visceral fat reduction will continue to modulate autoimmune load.
DHEA and muscle
DHEA 35 mg/day may modestly support lean mass via androgen conversion. 5b-dominant metabolism pattern (DUTCH) means less direct androgenic effect, but general anabolic environment is supportive.